Announcements Trials
Browse Landscape

Phase

Phase NA 12Phase 3 3Phase 2 2Phase 4 1

Status

Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Genitourinary 1Classical hematology 1CNS 1

Conditions

Pancreatic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 780Fluorouracil 638Capecitabine 575Gemcitabine 478Leucovorin 459Bevacizumab 445Irinotecan 444Cisplatin 338Radiotherapy 283Cetuximab 252Paclitaxel 180S 1 (combination) 176pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 131apatinib 131130-nm albumin-bound paclitaxel 128Folfox protocol 121durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106regorafenib 102Surgical Procedures, Operative 102Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Dietary Supplements × Gastrointestinal × Clear all
NCT07064668 2025-07-15

Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study

Tongji Hospital

Phase 2 Not yet recruiting
300 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT02745197 2024-09-19

A Study to See Whether a Nutritional Supplement is Beneficial for Patients With Pancreatic Cancer

University of Alberta

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡